Longboard Pharmaceuticals, Inc.
LBPHDelisted Dec 2, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001832168
Longboard Pharmaceuticals, Inc. was delisted on Dec 2, 2024; its insiders filed their last Form 4 on Dec 2, 2024; 125 institutions reported holding it in 13F filings for Q3 2024, worth $1.33B in total; Viking Global Investors was the only superinvestor holding it.
13F holders, Q2 2022
Institutional positions in Longboard Pharmaceuticals, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −1 vs. Q1 2022
- Shares held
- 7.54M
- −75.0K (−1.0%) vs. Q1 2022
- Total value
- $23.3M
- −$16.8M (−41.9%) vs. Q1 2022
- New holders
- 2
- 5 more added
- Sold out
- 3
- 7 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LBPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 125 | $1.33B |
| Q2 2024 | 100 | $1.05B |
| Q1 2024 | 105 | $819.5M |
| Q4 2023 | 52 | $99.7M |
| Q3 2023 | 51 | $87.1M |
| Q2 2023 | 50 | $106.7M |
| Q1 2023 | 25 | $51.5M |
| Q4 2022 | 18 | $23.3M |
| Q3 2022 | 19 | $27.0M |
| Q2 2022 | 20 | $23.3M |
| Q1 2022 | 21 | $40.1M |
| Q4 2021 | 21 | $37.8M |
| Q3 2021 | 20 | $68.2M |
| Q2 2021 | 17 | $71.7M |
| Q1 2021 | 22 | $142.8M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Longboard Pharmaceuticals, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,273,221 | $7.02M | 0.54% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 1,511,739 | $4.67M | 0.00% | −5000.0% | Reduced |
| Millennium Management LLC | 1,043,216 | $3.22M | 0.00% | −2,713−0.3% | Reduced |
| FMR LLC | 891,506 | $2.75M | 0.00% | −157,456−15.0% | Reduced |
| Farallon Capital Management, L.L.C. | 810,500 | $2.50M | 0.01% | 00.0% | Unchanged |
| Citigroup Inc | 325,000 | $1.00M | 0.00% | +170,207+110.0% | Added |
| Vanguard Group Inc | 303,749 | $938.0K | 0.00% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 113,500 | $351.0K | 0.01% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 70,000 | $216.0K | 0.00% | 00.0% | Unchanged |
| Integral Health Asset Management, LLC | 57,335 | $177.0K | 0.04% | +9,735+20.5% | Added |
| TD Asset Management Inc | 37,611 | $116.0K | 0.00% | −130.0% | Reduced |
| Alyeska Investment Group, L.P. | 27,084 | $84.0K | 0.00% | −35,416−56.7% | Reduced |
| BlackRock Inc. | 21,731 | $67.0K | 0.00% | −8,938−29.1% | Reduced |
| Laurion Capital Management LP | 20,918 | $65.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 15,531 | $47.0K | 0.00% | +354+2.3% | Added |
| Bank of America Corp | 13,823 | $43.0K | 0.00% | −11,544−45.5% | Reduced |
| Tower Research Capital LLC (TRC) | 3,146 | $10.0K | 0.00% | +2,918+1,279.8% | Added |
| Wells Fargo & Company | 35 | $0 | 0.00% | +3+9.4% | Added |
| UBS Group AG | 64 | $0 | 0.00% | +64 | New |
| Advisor Group Holdings, Inc. | 1 | $0 | 0.00% | +1 | New |
| Bailard, Inc. | 0 | $0 | 0.00% | −21,200−100.0% | Sold out |
| Veritable, L.P. | 0 | $0 | 0.00% | −20,534−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −5−100.0% | Sold out |